Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Chinook Therapeutics’ Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress

By John F. Heerdink, Jr.


Chinook Therapeutics, Inc. (NASDAQ: KDNY) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. 

On March 30th Chinook announced upcoming data presentations at the ISN World Congress of Nephrology 2021 from April 15 – 19, 2021 and the 58th ERA-EDTA Congress from June 5 – 8, 2021. 


The following abstracts will be presented as poster presentations at the ISN World Congress of Nephrology 2021:

Atrasentan

Abstract WCN21-0848

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)

Author:

Hiddo J. L. Heerspink, University Medical Center Groningen, Groningen, Netherlands

 

Abstract WCN21-0717

Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)

Author:

Marianne Camargo, M.D.

Abstract WCN21-0358

Selective ETA Antagonist Atrasentan, Rapidly Reduces Albuminuria and Downregulates Intra-renal Pro-Inflammatory and Pro-Fibrotic Transcriptional Networks in the g-ddY Mouse Model of Spontaneous IgA Nephropathy

Author:

Andrew King, D.V.M., PhD

Abstract WCN21-0398

Human Renal Mesangial Cell Activation Induced by Endothelin-1 or IgA Nephropathy Patient Immune Derived Complexes is Blocked by Selective ETA Antagonist Atrasentan

Author:

Jennifer Cox, Ph.D.

BION-1301

Abstract WCN21-0706

A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous (IV) and Subcutaneous (SC) Routes

Author:

Jeannette Lo, Ph.D.

CHK-336

Abstract WCN21-0612

Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Hyperoxaluria

Author:

Jennifer Cox, Ph.D.


The following abstract was selected for oral presentation at the 58th ERA-EDTA Congress:

Presentation ID FC040

Interim Results of Phase 1 and 2 Trials to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of BION-1301 in Patients with IgA Nephropathy

Author:

Jonathan Barratt, Ph.D., F.R.C.P, University of Leicester & Leicester General Hospital

Session:

Treatment & outcome of glomerulonephritis

The following abstracts will be presented as mini-oral (poster) presentations at the 58th ERA-EDTA Congress:

Atrasentan

Abstract ID 1547

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)

Author:

Hiddo J. L. Heerspink, University Medical Center Groningen, Groningen, Netherlands

BION-1301

Abstract ID 1024

Design of a Phase 1, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy (ADU-CL-19) and A Multicenter, Open-Label Extension (OLE) Study for Patients with Immunoglobulin A Nephropathy (IgAN) Who Participated in A Prior Clinical Study of BION-1301 (ADU-CL-24)

Author:

Jonathan Barratt, Ph.D., F.R.C.P, University of Leicester & Leicester General Hospital


KIDNEY DISEASE 

Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. These dynamics have converged to create attractive opportunities for the development of precision therapies.

One of the key challenges in studying and treating kidney disease has been the complexity of the organ, with nearly 30 distinct cell types, each with its own function and purpose. This cellular diversity and structure has made understanding the mechanisms associated with kidney function loss challenging. However, the recent development of single-cell RNA sequencing of different kidney cell populations presents a new opportunity to clearly understand the molecular mechanisms of kidney function and disease. Chinook utilizes single-cell RNA sequencing techniques and proprietary datasets developed by their academic founder, Ben Humphreys (Washington University, St. Louis, MO), to gain unprecedented insights into kidney disease mechanisms.

The cellular complexity of the kidney also presents barriers to developing translationally-relevant models of human kidney diseases. Recently, kidney organoids and patient-derived 3D kidney cellular systems have emerged as advanced preclinical models to study kidney disease. Chinook partners with leading academic collaborators to apply these novel human organoids as translational model systems for target validation in indications such as polycystic kidney disease. In addition, we’ve established patient-derived 3D cellular models of polycystic kidney disease in-house. We believe our approach using these and other validation tools provides significant insights into human disease mechanisms and allows us to select and validate key targets that are central drivers of human kidney diseases.


CHINOOK’s LATEST PUBLICATIONS

Single Cell Transcriptomic Analysis to Define Cellular Heterogeneity in Human ADPKD
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020

Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxaluria
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020

A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020

Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers (Encore)
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020

Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers (Encore)
Asian Pacific Congress of Nephrology | October 2020





You can also learn more and track Chinook’s progress at Vista’s Chinook Therapeutics’ Dedicated Page within our VPWatchlist section of our website.



Post View Count : 396


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us